253 related articles for article (PubMed ID: 27535784)
21. Microbial gatekeepers: unraveling the role of the gut microbiota enzyme DPP4 in diabetes management.
Liao L; Lin F; Gao J
Trends Biochem Sci; 2024 Feb; 49(2):99-100. PubMed ID: 37770288
[TBL] [Abstract][Full Text] [Related]
22. Navigating the chemical space of dipeptidyl peptidase-4 inhibitors.
Shoombuatong W; Prachayasittikul V; Anuwongcharoen N; Songtawee N; Monnor T; Prachayasittikul S; Prachayasittikul V; Nantasenamat C
Drug Des Devel Ther; 2015; 9():4515-49. PubMed ID: 26309399
[TBL] [Abstract][Full Text] [Related]
23. Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease.
Remm F; Franz WM; Brenner C
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):185-93. PubMed ID: 27533760
[TBL] [Abstract][Full Text] [Related]
24. Emerging Role of Dipeptidyl Peptidase-4 in Autoimmune Disease.
Huang J; Liu X; Wei Y; Li X; Gao S; Dong L; Rao X; Zhong J
Front Immunol; 2022; 13():830863. PubMed ID: 35309368
[TBL] [Abstract][Full Text] [Related]
25. The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury.
Wang XM; Holz LE; Chowdhury S; Cordoba SP; Evans KA; Gall MG; Vieira de Ribeiro AJ; Zheng YZ; Levy MT; Yu DM; Yao TW; Polak N; Jolly CJ; Bertolino P; McCaughan GW; Gorrell MD
Immunol Cell Biol; 2017 May; 95(5):443-453. PubMed ID: 27899813
[TBL] [Abstract][Full Text] [Related]
26. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.
Lim SW; Jin JZ; Jin L; Jin J; Li C
Korean J Intern Med; 2015 Nov; 30(6):759-70. PubMed ID: 26552451
[TBL] [Abstract][Full Text] [Related]
27. A novel multi-epitope vaccine based on Dipeptidyl Peptidase 4 prevents streptozotocin-induced diabetes by producing anti-DPP4 antibody and immunomodulatory effect in C57BL/6J mice.
Li Z; Fang J; Jiao R; Wei X; Ma Y; Liu X; Cheng P; Li T
Biomed Pharmacother; 2017 May; 89():1467-1475. PubMed ID: 28376584
[TBL] [Abstract][Full Text] [Related]
28. DPP4 Inhibition Ameliorates Cardiac Function by Blocking the Cleavage of HMGB1 in Diabetic Mice After Myocardial Infarction.
Sato A; Suzuki S; Watanabe S; Shimizu T; Nakamura Y; Misaka T; Yokokawa T; Shishido T; Saitoh SI; Ishida T; Kubota I; Takeishi Y
Int Heart J; 2017 Oct; 58(5):778-786. PubMed ID: 28966327
[TBL] [Abstract][Full Text] [Related]
29. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.
Gong Q; Rajagopalan S; Zhong J
Int J Cardiol; 2015 Oct; 197():170-9. PubMed ID: 26142202
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats.
Chua S; Lee FY; Tsai TH; Sheu JJ; Leu S; Sun CK; Chen YL; Chang HW; Chai HT; Liu CF; Lu HI; Yip HK
J Transl Med; 2014 Dec; 12():357. PubMed ID: 25496837
[TBL] [Abstract][Full Text] [Related]
31. Targeting cluster of differentiation 26 / dipeptidyl peptidase 4 (CD26/DPP4) in organ fibrosis.
Ohm B; Moneke I; Jungraithmayr W
Br J Pharmacol; 2023 Nov; 180(22):2846-2861. PubMed ID: 36196001
[TBL] [Abstract][Full Text] [Related]
32. Role of dipeptidyl peptidase-4 as a potentiator of activin/nodal signaling pathway.
Park DS; Kim K; Jang M; Choi SC
BMB Rep; 2018 Dec; 51(12):636-641. PubMed ID: 30463640
[TBL] [Abstract][Full Text] [Related]
33. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.
Avogaro A; Fadini GP
Diabetes Care; 2014 Oct; 37(10):2884-94. PubMed ID: 25249673
[TBL] [Abstract][Full Text] [Related]
34. Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior WS; Godoy-Matos AF; Kraemer-Aguiar LG
Biomed Res Int; 2015; 2015():816164. PubMed ID: 26146634
[TBL] [Abstract][Full Text] [Related]
35. Development of a
Yazbeck R; Jaenisch S; Squire M; Abbott CA; Parkinson-Lawrence E; Brooks DA; Butler RN
Sci Rep; 2019 Mar; 9(1):4906. PubMed ID: 30894647
[TBL] [Abstract][Full Text] [Related]
36. Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM).
Mora-Rodríguez JM; Sánchez BG; Bort A; Díaz-Yuste A; Ballester-González R; Arrieta F; Sebastián-Martín A; Díaz-Laviada I
Life Sci; 2024 Jan; 336():122292. PubMed ID: 38030058
[TBL] [Abstract][Full Text] [Related]
37. New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxytocin.
Chittepu VCSR; Kalhotra P; Osorio-Gallardo T; Jiménez-Martínez C; Torre RRR; Gallardo-Velazquez T; Osorio-Revilla G
Molecules; 2019 Oct; 24(21):. PubMed ID: 31661941
[TBL] [Abstract][Full Text] [Related]
38. The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.
Rhee NA; Østoft SH; Holst JJ; Deacon CF; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Sep; 171(3):353-62. PubMed ID: 24935932
[TBL] [Abstract][Full Text] [Related]
39. The protective role of DPP4 inhibitors in atherosclerosis.
Liu H; Guo L; Xing J; Li P; Sang H; Hu X; Du Y; Zhao L; Song R; Gu H
Eur J Pharmacol; 2020 May; 875():173037. PubMed ID: 32097656
[TBL] [Abstract][Full Text] [Related]
40. DPP4 in Diabetes.
Röhrborn D; Wronkowitz N; Eckel J
Front Immunol; 2015; 6():386. PubMed ID: 26284071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
